Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia

15 novembre 2026 aggiornato da: Kind Pharmaceuticals LLC

A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

240

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Capable of providing signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  • Body weight from 45-140 kg inclusive.

  • A diagnosis of CKD confirmed at screening, CKD stage 3, 4, or 5 defined by eGFR <60 mL/min/1.73 m2.

  • Prior ESA use and Hb levels:

    1. ESA-naïve: Defined as no use of any ESA treatment for at least 12 weeks before randomization; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be ≥7.5 g/dL and <10.0 g/dL.
    2. ESA-treated: Defined as having received an approved ESA, administered intravenously or subcutaneously, for at least 6 weeks prior to randomization, with no change in ESA product and no treatment interruption exceeding two consecutive weeks; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be 9.0-11.0 g/dL inclusive.
  • TSAT ≥20% or ferritin ≥100 ng/mL at screening test.

  • Serum folate and vitamin B12 ≥ lower limit normal (LLN) at screening test

  • Total bilirubin ≤1.5× upper limit normal (ULN). For Gilbert's Syndrom, <3×ULN.

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN

  • No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia

  • No other primary cause for anemia other than CKD.

Exclusion Criteria:

  • Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
  • Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent autoimmune disease with inflammatory symptoms.
  • History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment.
  • Clinically significant bleeding within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
  • History or concurrent hemosiderosis, hemochromatosis or hyper-coagulable condition.
  • Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >110 mmHg during the screening period.
  • History of stroke, transient ischemic attack, myocardial infarction, thromboembolic event , pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
  • Participants with a history of significant liver disease or active liver disease.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • Having undergone blood transfusion and/or a surgical procedure that caused major blood loss within 8 weeks before the screening assessment
  • Participants that have major surgery planned during the study period.
  • Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
  • Serum albumin (ALB) < 2.5 g/dL at screening test.
  • Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody at the screening assessment, or positive for human immunodeficiency virus in a past test.
  • Having received any investigational drug in an interventional clinical trial within 5 weeks before the randomization.
  • A known history of allergic reactions to ESA treatment.
  • History of serious drug allergies.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: AND017

AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients

Comparatore attivo: ESA

ESA injection and dose based on package insert and local practice

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The mean Hb levels averaged over Week 25-29
Lasso di tempo: Week 25 to Week 29

Evaluate the efficacy of AND017 for treatment of anemia in patients with NDD-CKD

Week 25 to Week 29

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of responders over the main treatment period
Lasso di tempo: Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

defined as patients who meet either of the following criteria: For patients with baseline Hb 9.0 g/dL: mean Hb ≥ 10.0 g/dL during Weeks 25-29 and a change from baseline ≥ -1.0 g/dL during Weeks 25-29; For patients with baseline Hb < 9.0 g/dL: an increase in Hb from baseline ≥ 1.0 g/dL during Weeks 3-29

Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29
Lasso di tempo: Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29

Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
The percentage of response visits over the entire study treatment
Lasso di tempo: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

Response visit is defined as after first reaching ≥ 10.0 g/dL, Hb maintained within the target range of 10.0-11.0 g/dL

Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
The cumulative incidence of Hb non-response over Weeks 5-29
Lasso di tempo: Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

Non-response is defined as Hb < 10.0 g/dL and an increase from baseline < 1.0 g/dL

Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
Change from baseline in serum iron over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in ferritin over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in transferrin over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in transferrin saturation over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in total iron binding capacity over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
The percentage of patients received intravenous iron treatment during the entire study
Lasso di tempo: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
During the entire treatment period, the mean weekly dose of intravenous iron treatment (mg)
Lasso di tempo: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
During the entire treatment period, the time to first initiation of intravenous iron treatment (Day)
Lasso di tempo: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in total cholesterol over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in low density lipoprotein over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in high density lipoprotein over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in triglycerides over the entire treatment period
Lasso di tempo: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 febbraio 2027

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

15 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2026

Primo Inserito (Effettivo)

20 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

20 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • AND017-US-303

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .